Therefore, comparison of the effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2is) as a medication associated with weight loss and metabolic off-load with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4i) as weight-neutral agents could be of interest also in terms of cancer. This evidence concerns the gene SLC5A2 and cancer.